Eli Lilly & Co. makes second major pharmaceutical deal this year by paying cancer drug specialists Loxo Oncology $8 billion.
Effectively ending their self-imposed halt this year, drugmakers will start the new year with drug price increases.
GlaxoSmithKline is beefing up its pharmaceuticals business with the acquisition of Tesaro for its strength in cancer treatment drugs, and that’s just the beginning.
Centrexion Therapeutics will allot the funding to the next phase of its CNTX-4975 drug.
Oramed's research team developed a pill that can introduce insulin to the body without breaking down from the different enzymes of the gastrointestinal tract.